C-reactive Protein in Patients with Metastatic Clear Cell Renal Carcinoma: An Important Biomarker for Tumor-associated Inflammation
Open Access
- 1 January 2006
- journal article
- research article
- Published by SAGE Publications in Biomarker Insights
- Vol. 1, 87-98
Abstract
Two consecutive multi-center phase II trials were designed to prove the hypothesis, whether therapeutic modeling of tumor-associated inflammatory processes could result in improved tumor response. Therapy in both trials consisted of low-dose capecitabine 1g/m2 twice daily p.o. for 14 days, every 3 weeks, day 1+, and rofecoxib 25 mg daily p.o., day 1+ (from 11/04 etoricoxib 60 mg daily instead) plus pioglitazone 60 mg daily p.o., day 1+. In study II low-dose IFN-α 4.5 MU sc. three times a week, week 1+, was added until disease progression. Eighteen, and 33 patients, respectively, with clear cell renal carcinoma and progressive disease were enrolled. Objective response (48%) was exclusively observed in study II (PR 35%, CR 13%), and paralleled by a strong CRP response after 4 weeks on treatment, p = 0.0005, in all 29 pts (100%) with elevated CRP levels. Median progression-free survival could be more than doubled from a median of 4.7 months (95% CI, 1.0 to 10.4) to 11.5 months (6.8 to 16.2) in study II, p = 0.00001. Median overall survival of population II was 26 months. Efficacious negative regulation of tumor-associated inflammation by transcription modulators may result in a steep increase of tumor response and survival.Keywords
This publication has 51 references indexed in Scilit:
- Interleukin-2/interferon-α2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)British Journal of Cancer, 2006
- A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γNature, 2005
- Curcumin inhibits interferon-α induced NF-κB and COX-2 in human A549 non-small cell lung cancer cellsBiochemical and Biophysical Research Communications, 2005
- PPARγ as a therapeutic target for tumor angiogenesis and metastasisCancer Biology & Therapy, 2005
- Randomized Phase II/III Trial of Interferon Alfa-2a With and Without 13-cis-Retinoic Acid in Patients With Progressive Metastatic Renal Cell Carcinoma: The European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951)Journal of Clinical Oncology, 2005
- von Hippel-Lindau Protein-Mediated Repression of Tumor Necrosis Factor Alpha Translation Revealed through Use of cDNA ArraysMolecular and Cellular Biology, 2003
- Expression of Peroxisome Proliferator-Activated Receptor γ in Renal Cell Carcinoma and Growth Inhibition by Its AgonistsBiochemical and Biophysical Research Communications, 2001
- Human Renal Cancers Resistant to IFN's Antiproliferative Action Exhibit Sensitivity to IFN's Gene-Inducing and Antiviral ActionsJournal of Urology, 1996
- Induction of Interleukin 6 (IL-6) by Hypoxia in Vascular CellsJournal of Biological Chemistry, 1995
- Identification of the von Hippel-Lindau Disease Tumor Suppressor GeneScience, 1993